TY - JOUR. T1 - Effect of trivalent arsenicals on cell proliferation in mouse and human microvascular endothelial cells. AU - Dodmane, Puttappa R.. AU - Arnold, Lora L. AU - Pennington, Karen L.. AU - Singh, Rakesh K. AU - Cardoso, Ana Paula Ferragut. AU - Cohen, Samuel Monroe. PY - 2015/5/1. Y1 - 2015/5/1. N2 - Chronic exposure to high levels of inorganic arsenic (iAs) has been associated with cancerous and non-cancerous health effects, including cardiovascular effects. However, the mechanism for a presumed toxic effect of arsenic on vascular tissue is not clear. Our working hypothesis is that inorganic trivalent arsenic and its methylated metabolites react with cysteine-containing cellular proteins and alter their function leading to adverse events such as cytotoxicity or proliferation. In this study, human microvascular endothelial cells (HMEC1) and mouse microvascular endothelial cells (MFP-MVEC) were exposed to arsenite (iAsIII), monomethylarsonous acid (MMAIII), or dimethylarsinous acid ...
Stock Photo 4128R-18191: Download Arsenic trioxide, molecular model. Precursor to arsenic compounds, including organoarsenic compounds. Atoms are represented as spheres and are colour_coded: arsenic violet and oxygen red. Stock Photos. Search over 12 million royalty free images and rights managed stock photography
During the last decade, ATO has been used effectively to treat both newly diagnosed and relapsed APL patients, with patients showing complete remission after low dose ATO treatment [4]. The anti-cancer ability of ATO is not limited to APL [36] and many other tumors in animal models have been shown to be sensitive to ATO treatment [37, 38]. However, the lack of information on sites of action for ATO cytotoxicity in tumor types other than APL has limited its uptake for the treatment of other cancers until recent years [5].. In this study, we have demonstrated that complex IV of the ETC is a target for ATO. From a panel of ETC inhibitors, the decrease in ROS, decrease in ATP production and MMP depolarisation caused by low dose ATO treatment of T-47D cells was reproduced only by cyanide, a well characterised complex IV inhibitor (Figure 5). Direct measurement of cytochrome C oxidase activity in whole cells treated with ATO confirmed the ability of ATO to inhibit this enzyme activity directly. The ...
Citation: Ritchie, A.W., Edmonds, J.S., Goessler, W. and Jenkins, R.O. (2004) An origin for arsenobetaine involving bacterial formation of an arsenic-carbon bond. FEMS Microbiology Letters. 235 (1) pp.95-99 ...
Gentaur molecular products has all kinds of products like :search , Ato \ 100V_120V AC adapter for FLAT_Viewer \ 2196161 for more molecular products just contact us
Gentaur molecular products has all kinds of products like :search , Ato \ EA_25 Column End Assembly \ 1293622 for more molecular products just contact us
平成29年度「ジフェニルアルシン酸等に係る健康影響に関する調査研究」モデル動物を用いたジフェニルアルシン酸(DPAA)の生体影 ...
There are 15 Chapters to deeply display the Global Gallium Arsenide market.. Chapter 1, to describe Gallium Arsenide Introduction, product scope, market overview, market opportunities, market risk, market driving force;. Chapter 2, to analyze the top manufacturers of Gallium Arsenide, with sales, revenue, and price of Gallium Arsenide, in 2016 and 2018;. Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2018;. Chapter 4, to show the Global market by regions, with sales, revenue and market share of Gallium Arsenide, for each region, from 2012 to 2018;. Chapter 5, 6, 7, 8 and 9, to analyze the key regions, with sales, revenue and market share by key countries in these regions;. Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2012 to 2018;. Chapter 12, Gallium Arsenide market forecast, by regions, type and application, with sales and revenue, ...
TY - JOUR. T1 - Arsenic trioxide. T2 - Its use in the treatment of acute promyelocytic leukemia. AU - Sanz, Miguel A.. AU - Lo-Coco, Francesco. PY - 2006. Y1 - 2006. N2 - Acute promyelocytic leukemia (APL) represents approximately 10-15% of all adult cases of acute myeloid leukemia and is characterized by a unique genetic abnormality and frequent association with a severe hemorrhagic diathesis. An arsenic trioxide formulation for intravenous infusion has been developed and is currently licensed for the induction of remission and consolidation in adult patients with relapsed/refractory APL. Several studies have shown that arsenic trioxide is highly effective in the treatment of relapsed/refractory patients with APL, achieving remission rates of ,80%, high rates of molecular remission, and durable periods of disease-free survival. Furthermore, recent studies indicate that arsenic trioxide may also have a role in the treatment of newly diagnosed patients, either as a single agent or in combination ...
TRIVENI INTERCHEM PVT. LTD. - Exporter, Manufacturer, Distributor, Supplier, Trading Company of Arsenides Aluminium arsenide,Aluminium gallium arsenide,Aluminium indium arsenide,Arsenide,Boron arsenide,Cadmium arsenide,Gallium arsenide,Gallium arsenide phosphide,Gallium manganese arsenide, India
Cycle 1 cytarabine 10 mg/m^2 was administered subcutaneously (sc) twice daily (bid) on days 1-14. 0.25 mg/kg arsenic trioxide was administered intravenously (iv) on days 1-5 and days 8-12. Cycle 2 A second identical cycle of cytarabine and arsenic trioxide was given to patients with persistent disease. Patients who achieved complete remission (CR), complete remission with incomplete platelet count recovery (CRp), or partial remission (PR) after 1 or 2 cycles received a 14-day consolidation cycle of cytarabine and arsenic trioxide with the doses and schedule identical to the initial cycle. A recovery period of up to 4 weeks between the attainment of CR, CRp, or PR and the initiation of consolidation treatment was allowed. Patients who completed consolidation treatment started maintenance treatment of arsenic trioxide 0.25 mg/kg iv on days 1 and 4 and cytarabine 10 mg/m^2 sc bid on days 1 through 7 of a 28-day cycle ...
The purpose of this study is to study the effect of an anticancer drug, Arsenic Trioxide, in patients with small cell lung cancer who have failed at least one standard chemotherapy regimen as well as patients who are unable to tolerate the standard treatment for their cancer. The investigators seek to establish the safety of and efficacy of Arsenic Trioxide in this patient group. The study will include up to 36 participants with small cell lung cancer.. The investigators want to find out what effects, good or bad, that the study drug has on your cancer. This study will also look at specific biomarkers in your blood and in the tumor tissue which may help the investigators to determine if the levels of these biomarkers are related to tumor response to treatment.. Arsenic Trioxide, also known by the brand name, Trisenox, is a chemotherapy drug approved by the Food and Drug Administration (FDA) for the treatment of a specific type of blood cancer called Acute Promyelocytic Leukemia. It works in part ...
Arsenic Trioxide - Get up-to-date information on Arsenic Trioxide side effects, uses, dosage, overdose, pregnancy, alcohol and more. Learn more about Arsenic Trioxide
Arsenic is a highly poisonous metallic element in the nitrogen family of group Va in the periodic table. Symbol As; aomic number 33; atomic mass 74.9216; melting point ca 817°C; sublimation point ca 613°C; specific gravity 6.80 or 7.004; 5.73; valence -3, 0, +3, or +5.; electronic config. [Ar]3d104s24p3. It appears in three allotropic forms, yellow, black, and gray. The stable form is a brittle, steel-gray hexagonal solid that oxidizes rapidly in air, and at high temperatures burns to form a white cloud of arsenic trioxide. Arsenic and some arsenic compounds sublime when heated and convert to gaseous form. Arsenic is an omnipresent element as arsenic minerals in the various lithosphere or fossil fuels including realgar, orpiment, and arsenopyrite. It is prepared commercially from arsenical pyrites (sulfide ores) by condensation of sublimed gas and by the reduction of white arsenic with carbon. This element contributes hardness and is used in preparing alloys for hard and corrosion-resistant ...
JERUSALEM--(BUSINESS WIRE)--Jan. 15, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that the U.S. Food and Drug Admini, Teva Announces U.S. FDA Approval of TRISENOX® (arsenic trioxide) Injection for First Line Treatment of Acute Promyelocytic Leukemia
JERUSALEM--(BUSINESS WIRE)--Jan. 15, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that the U.S. Food and Drug Admini, Teva Announces U.S. FDA Approval of TRISENOX® (arsenic trioxide) Injection for First Line Treatment of Acute Promyelocytic Leukemia
Inhibition of mitochondrial protein translation sensitizes melanoma cells to arsenic trioxide cytotoxicity via a reactive oxygen species dependent mechanism. Benjamin D. Bowling, Nicole Doudican, Prashiela Manga, and Seth J. Orlow, Department of Dermatology, NYU School of Medicine, New York City, New York. (Sponsored by David J. Leffell, Department of Dermatology, Yale University School of Medicine). Current standard chemotherapeutic regimens for malignant melanoma are unsatisfactory. Although in vitro studies of arsenic trioxide (ATO) have demonstrated promise against melanoma, recent phase II clinical trials have failed to show any significant clinical benefit when used as a single agent. To enhance the efficacy of ATO in the treatment of melanoma, we sought to identify compounds that potentiate the cytotoxic effects of ATO in melanoma cells. Through a screen of 2000 marketed drugs and naturally occurring compounds, and subsequent mechanistic testing, a variety of antibiotic inhibitors of ...
Description of the drug arsenic trioxide Intravenous. - patient information, description, dosage and directions. What is arsenic trioxide Intravenous!
Teva Receives FDA Priority Review for First Line Use of TRISENOX® (arsenic trioxide) in Patients with Low to Intermediate Risk Acute Promyelocytic Leukemia (APL)
Learn about Trisenox (Arsenic Trioxide Injection) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related medications.
(2010) A., S.D.. Blood Reviews. Over the last 17years, clinical trials conducted worldwide have demonstrated the efficacy of arsenic trioxide (As2O3) in the treatment of relapsed acute promyelocytic leukemia (APL). Currently, the role of As2O3 in front-line therapy is under investigation. Recent ...
PubMed journal article: Arsenic Trioxide, Itraconazole, All-Trans Retinoic Acid and Nicotinamide: A Proof of Concept for Combined Treatments with Hedgehog Inhibitors in Advanced Basal Cell Carcinoma. Download Prime PubMed App to iPhone, iPad, or Android
Arsenic trioxide (As2O3) has shown anti-tumour activity against a variety of solid tumours in vitro. However, the mechanisms responsible for its cytotoxicity against ovarian carcinoma remain elusive. In this thesis, the molecular determinants of its effects and factors mediating its chemoresistance in ovarian cancer cells were investigated. It was found that As2O3 treatment caused both apoptosis induction and caspase-independent cell death involving mitochondrial dysfunction. This was accompanied by endoplasmic reticulum stress induction and an increase in intracellular glutathione (GSH) level. The latter was in turn prevented by the concurrent use of GSH modulator, buthionine sulfoximine but not ascorbic acid. Gene expression analysis of arsenic-resistant OVCAR-3 (OVCAR-3/AsR) cells showed the involvement of multiple factors mediating its chemoresistance. Of particular interest, a genetic hub involving elevated interleukin 1A signalling was identified. This could consecutively modulate the ...
OBJECTIVE: To investigate the effect of drug resistance by arsenic trioxide (As(2)O(3)) and its possible mechanism in human breast cancer cell line MCF-7/ADM. METHODS: Cytotoxicity of As(2)O(3) and the sensibility to adriamycin (ADM) in MCF-7/ADM cel
Figure 4: Arsenic Trioxide Suppresses Tumor Growth through Antiangiogenesis via Notch Signaling Blockade in Small-Cell Lung Cancer
Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery This study is currently…
AMBICA PHARMA - Manufacturer,Supplier,Exporter of Arsenic Trioxide from India. We offer best quality of products at a best price rate.
This epidemiological study investigated the association between β-cell function (a predictive factor of diabetes development) and the organic arsenic arsenobetaine (an agent less toxic to humans). Urine arsenobetaine was revealed to be associated with HOMA-β in the normal population (without diabetes), especially in males, even after adjusting for factors affecting diabetes and β-cell function, while no association was shown with HOMA-IR which is associated with insulin resistance.. Despite several conflicting results, arsenic has been reported to be correlated with diabetes in many epidemiological studies [6, 9, 23-31], and arsenic can affect insulin resistance and β-cell function [7]. In some experimental studies, arsenite was found to induce oxidative stress in pancreatic β-cells and reduce insulin transcription and secretion [32, 33], caused by the altered expression of essential genes such as the Pdx1 gene [34, 35] and insulin gene [36] for pancreas development, insulin production, and ...
An ensemble Monte Carlosimulation is used to compare high field electron transport in bulk InAs, InP and GaAs. In particular, velocity overshoot and electron transit times are examined. For all materials, we find that electron velocity overshoot only occurs when the electric field is increased to a value above a certain critical field, unique to each material. This critical field is strongly dependent on the material, about 3 kV/cm for InAs, 10 kV/cm for InP and 5 kV/cm for the case of GaAs, We find that InAs exhibits the highest peak overshoot velocity and that this velocity overshoot lasts over the longest distances when compared with GaAs and InP. Finally, we estimate the minimum transit time across a 1 μm InAs sample to be about 2 ps. Similar calculations for InP and GaAs yield 6.6 and 5.4 ps, respectively. We find that the optimal cutoff frequency for an ideal InAs based device ranges from around 79 GHz when the device thickness is set to 1 μm. We thus suggest that indium arsenide offers great
Purpose: It was recently reported that the organic arsenic compound darinaparsin (DPS) is a cytotoxin and radiosensitizer of tumor cells in vitro and in subcutaneous xenograft tumors. Surprisingly, it was also found that DPS protects normal intestinal crypt epithelial cells (CECs) from clonogenic death after ionizing radiation (IR). Here we tested the DPS radiosensitizing effect in a clinically relevant model of prostate cancer and explored the radioprotective effect and mechanism of DPS on CECs. Methods and Materials: The radiation modification effect of DPS was tested in a mouse model of orthotopic xenograft prostate cancer and of IR-induced acute gastrointestinal syndrome. The effect of DPS on CEC DNA damage and DNA damage responses was determined by immunohistochemistry. Results: In the mouse model of IR-induced gastrointestinal syndrome, DPS treatment before IR accelerated recovery from body weight loss and increased animal survival. DPS decreased post-IR DNA damage and cell death, ...
TY - JOUR. T1 - Pharmaceutical development of the novel arsenical based cancer therapeutic GSAO for phase I clinical trial. AU - Elliott, Moira. AU - Ford, S J. AU - Prasad, E. AU - Dick, L J. AU - Farmer, H. AU - Hogg, P J. AU - Halbert, G W. N1 - Copyright © 2012 Elsevier B.V. All rights reserved.. PY - 2012/4/15. Y1 - 2012/4/15. N2 - The novel organoarsenical GSAO, 4-(N-(S-glutathionylacetyl)amino) phenylarsonous acid, has potential anti-angiogenic capability with application in cancer where tumour metastasis relies on neo-vascularisation. As GSAO arsenic is trivalent, the arsenoxide moiety reacts with appropriately spaced cysteine residues on adenine nucleotide translocase (ANT) mitochondrial membrane protein. Molecular oxidation of the arsenic to the pentavalent structure, as in the degradant GSAA (4-(N-(S-glutathionylacetyl)amino) phenylarsonic acid), prevents sulphydryl interaction and risks abolition of activity. We report here on formulation studies aiming to produce a parenteral ...
Teva Pharmaceuticals USA, Inc. and its North American affiliates maintain this site for your personal information, education, and communication.
NEW ORLEANS-Two forms of arsenic are effective for inducing remissions in people with acute promyelocytic leukemia (APL), according to data presented at the ASH meeting. 1
Hydrogen passivation of Si δ-doped GaAs grown by molecular beam epitaxy. Swaminathan, V.; Asom, M. T.; Livescu, G.; Geva, M.; Stevie, F. A.; Pearton, S. J.; Lopata, J. // Applied Physics Letters;12/31/1990, Vol. 57 Issue 27, p2928 Hydrogen passivation of Si δ-doped GaAs grown by molecular beam epitaxy is studied. Just as in uniformily Si-doped GaAs, exposure of the δ-doped material to a low frequency (30 kHz) hydrogen plasma at 250 °C for 30 min deactivates the Si donors in the δ spikes. For samples with Si... ...
Thank you for your interest in spreading the word about Biochemical Society Transactions.. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.. ...
Learn about the potential side effects of Trisenox (arsenic trioxide). Includes common and rare side effects information for consumers and healthcare professionals.
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial
Data on 6,500 pesticides, insecticides and herbicides including toxicity, water pollution, ecological toxicity, uses and regulatory status.
https://doi.org/10.18632/oncotarget.5836 Wenchao Zhou, Lin Cheng, Yu Shi, Susan Q. Ke, Zhi Huang, Xiaoguang Fang, Cheng-wei Chu, Qi Xie, Xiu-wu Bian, Jeremy N. Rich, Shideng Bao
BACKGROUND: The studies have demonstrated that arsenic trioxide (ATO) in combination with all-trans retinoic acid (ATRA) takes effects in treatment of acute promyelocytic leukemia (APL) through different underlying mechanisms. This has established the molecular foundation of ATO plus ATRA therapy. Currently, ATO plus ATRA has also been widely used in clinical practice. OBJECTIVE: To assess the efficacy and safety of ATO in combination with ATRA for APL. SEARCH STRATEGY: The Cochrane Library (Issue 1, 2009), Cochrane Central Register of Controlled Trials (from 1970 to January 2009), MEDLINE (from 1978 to October 2008), EMBASE (from 1950 to March 2009), Chinese Biological Medical Literature Database (from 1978 to December 2008), CNKI (from 1994 to December 2008), China Medical Academic Conference Database (from 1994 to December 2008) were electronically searched ...
Find quality suppliers and manufacturers of 1309-64-4(Diantimony trioxide) for price inquiry. where to buy 1309-64-4(Diantimony trioxide).Also offer free database of 1309-64-4(Diantimony trioxide) including MSDS sheet(poisoning, toxicity, hazards and safety),chemical properties,Formula, density and structure, solution etc.
Despite the threat to human health and the environment, industrial poultry producers continue to use arsenical drugs to boost growth rates. A new study measured how much of this arsenic ends up in your meat.
Intro to industrial food animal production (IFAP); what are we feeding the animals; the use of antibiotics and arsenical drugs; and international expansion
From 1948 to 1975, nine out of eleven epidemiological studies show significant excess mortality from respiratory cancer among diverse occupations exposed to various inorganic arsenicals and demonstrate that such exposure is carcinogenic in three different tissues. Two of the studies show concomitant significant excess mortality from lymphatic cancer and one from skin cancer. Two studies reveal a d
Gallium Arsenide Nanoparticles / Nanopowder GaAs bulk & research qty manufacturer. Properties, SDS, Applications, Price. Free samples program. Term contracts & credit cards/PayPal accepted.
CPL 02-02-022 - CPL 2-2.22 - 29 CFR 1910.1018 Inspection and Compliance Procedures for the Permanent Occupation Exposure Standard for Inorganic Arsenic Compounds.
Nadar, Venkadesh Sarkarai; Yoshinaga, Masafumi; Pawitwar, Shashank S et al. (2016) Structure of the ArsI C-As Lyase: Insights into the Mechanism of Degradation of Organoarsenical Herbicides and Growth Promoters. J Mol Biol 428:2462-73 ...
The FODM121 series, FODM124, and FODM2701 consists of a gallium arsenide infrared emitting diode driving a phototransistor in a compact 4-pin mini-flat packag
The H11G1M and H11G2M are photodarlington-type optically coupled optocouplers. These devices have a gallium arsenide infrared emitting diode coupled with a si
POET Technologies has developed a gallium arsenide process to build electrical, optical, and electro-optical integrated circuits on one monolithic chip.